Deerfield Management Company, L.P. (Series C) Achilles Therapeutics PLC Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$5.81 - $9.93 $1.75 Million - $2.99 Million	-301,431 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$9.79 - $17.86 $4.88 Million - $8.9 Million	-498,569 Reduced 62.32%	301,431 $2.95 Million
Q1 2021 May 17, 2021	BUY	$16.55 - $16.55 $13.2 Million - $13.2 Million	800,000 New	800,000 $13.2 Million

Others Institutions Holding ACHL

# of Institutions

Shares Held

24.3M

Call Options Held

Put Options Held

Syncona Portfolio LTD Guernsey, Channel Islands, X0

11.1M
Shares

$12.9 Million
14.01% of portfolio
Bml Capital Management, LLC Zionsville, IN

4.1M
Shares

$4.76 Million
2.46% of portfolio
Fcpm Iii Services B.V. Naarden, P7

2.39M
Shares

$2.77 Million
0.42% of portfolio
Redmile Group, LLC San Francisco, CA

1.61M
Shares

$1.87 Million
0.11% of portfolio
Vestal Point Capital, LP New York, NY

1.5M
Shares

$1.74 Million
0.12% of portfolio

View Full List

About Achilles Therapeutics plc

Ticker ACHL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,774,000
Market Cap $47.3M
Description
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...

More about ACHL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account